Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;74(10):1215-1233.
doi: 10.1007/s00228-018-2498-1. Epub 2018 Jun 15.

Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews

Esther Letícia Amorim Ribeiro  1 , Tácio de Mendonça Lima  1 , Marcio Eduardo Bergamini Vieira  2 , Sílvia Storpirtis  1 , Patricia Melo Aguiar  3
Affiliations
Review

Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews

Esther Letícia Amorim Ribeiro et al. Eur J Clin Pharmacol. 2018 Oct.

Abstract

Purpose: To conduct an overview to summarize the efficacy and safety of aripiprazole for the treatment of schizophrenia.

Methods: A literature search was performed in PubMed, the Cochrane Library, LILACS, and the Centre for Reviews and Dissemination, for articles published until March 31, 2017. We included systematic reviews with meta-analyses of randomized controlled trials assessing the efficacy, and/or the safety of aripiprazole, for patients with schizophrenia. Two authors independently performed the study selection, data extraction, and quality assessment. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach and the Risk of Bias in Systematic Review (ROBIS) tool were used to appraise the quality of evidence and the risk of bias in the reviews, respectively.

Results: Fourteen studies fulfilled the inclusion criteria. Aripiprazole showed efficacy similar to that of both typical and atypical antipsychotic drugs (except olanzapine and amisulpride). Aripiprazole caused significantly lower weight gain and alterations in glucose and cholesterol levels, as compared to clozapine, risperidone, and olanzapine. In addition, aripiprazole caused significantly fewer general extrapyramidal side effects, less use of antiparkinsonian drugs, and akathisia, compared with typical antipsychotic drugs and risperidone. The overall quality of evidence in the reviews ranged from "very low" to "moderate," principally because of the risk of bias of original trials, inconsistency, and imprecision in the outcomes. According to the ROBIS tool, there are four reviews with "high" risk of bias and five with "unclear" risk of bias.

Conclusions: Aripiprazole exhibited efficacy similar to that of other antipsychotic drugs and a better safety profile than that of typical (i.e., less some extrapyramidal side effects) and atypical (i.e., less metabolic changes) antipsychotic drugs.

Keywords: Aripiprazole; Mental disorder; Overview; Schizophrenia; Systematic review.

PubMed Disclaimer

References

    1. Ann Clin Psychiatry. 2017 May;29(2):120-124 - PubMed
    1. J Clin Psychopharmacol. 2011 Dec;31(6):698-704 - PubMed
    1. Cureus. 2017 Apr 12;9(4):e1157 - PubMed
    1. Syst Rev. 2016 Apr 12;5:58 - PubMed
    1. Am J Psychiatry. 2009 Feb;166(2):152-63 - PubMed

MeSH terms

LinkOut - more resources